{"id":704947,"date":"2026-07-26T04:07:03","date_gmt":"2026-07-26T04:07:03","guid":{"rendered":"https:\/\/microscopemedia.com\/?p=704947"},"modified":"2026-07-26T04:07:03","modified_gmt":"2026-07-26T04:07:03","slug":"medicamentele-pentru-slabit-asociate-cu-un-risc-mai-mare-de-cadere-a-parului-arata-un-nou-studiu","status":"publish","type":"post","link":"https:\/\/microscopemedia.com\/?p=704947","title":{"rendered":"Medicamentele pentru sl\u0103bit, asociate cu un risc mai mare de c\u0103dere a p\u0103rului, arat\u0103 un nou studiu"},"content":{"rendered":"<div class=\"sgb-google-buttons\">\n<div class=\"display-flex justify-center google-logo\"><img decoding=\"async\" loading=\"lazy\" class=\"mg-x-auto\" width=\"30\" height=\"30\" src=\"https:\/\/microscopemedia.com\/wp-content\/uploads\/2026\/07\/medicamentele-pentru-slabit-asociate-cu-un-risc-mai-mare-de-cadere-a-parului-arata-un-nou-studiu.png\" alt><\/div>\n<\/p><\/div>\n<p data-start=\"242\" data-end=\"682\" id=\"p-0\">Cercetarea, realizat\u0103 de speciali\u0219ti de la Universitatea din Pennsylvania, sus\u021bine semnalele raportate anterior de autorit\u0103\u021bile de reglementare din Statele Unite \u0219i Marea Britanie.<\/p>\n<p data-start=\"684\" data-end=\"954\" id=\"p-1\">Oamenii de \u0219tiin\u021b\u0103 au analizat datele a aproape 50.000 de pacien\u021bi din cadrul University of Pennsylvania Health System, compar\u00e2nd persoanele tratate cu medicamente GLP-1 pentru diabet zaharat de tip 2 cu pacien\u021bi care primeau alte clase de medicamente antidiabetice, scrie <a href=\"https:\/\/news.sky.com\/story\/weight-loss-drugs-linked-to-increase-risk-of-hair-loss-researchers-say-13566156\" target=\"_blank\" rel=\"noopener\">Sky News<\/a>.<\/p>\n<h2 data-section-id=\"1do8r8q\" data-start=\"956\" data-end=\"1046\" id=\"chapter-0\"><span role=\"text\">Riscul este cu p\u00e2n\u0103 la 68% mai mare<\/span><\/h2>\n<p data-start=\"1048\" data-end=\"1315\" id=\"p-2\">\u00cen cadrul studiului au fost compara\u021bi 12.004 pacien\u021bi trata\u021bi cu agoni\u0219ti GLP-1 cu 15.221 de persoane care utilizau inhibitori SGLT-2. De asemenea, al\u021bi 11.964 de utilizatori ai medicamentelor GLP-1 au fost compara\u021bi cu 11.233 de pacien\u021bi trata\u021bi cu inhibitori DPP-4.<\/p>\n<p data-start=\"1317\" data-end=\"1485\" id=\"p-3\">Dup\u0103 ajustarea rezultatelor \u00een func\u021bie de factori precum v\u00e2rsta \u0219i greutatea corporal\u0103, cercet\u0103torii au constatat c\u0103 utilizarea medicamentelor GLP-1 a fost asociat\u0103 cu:<\/p>\n<ul data-start=\"1487\" data-end=\"1645\">\n<li data-section-id=\"13evjju\" data-start=\"1487\" data-end=\"1562\">un risc cu 37% mai mare de alopecie comparativ cu inhibitorii SGLT-2;<\/li>\n<li data-section-id=\"u041s0\" data-start=\"1563\" data-end=\"1645\">un risc cu 68% mai mare de c\u0103dere a p\u0103rului comparativ cu inhibitorii DPP-4.<\/li>\n<\/ul>\n<p data-start=\"1647\" data-end=\"1760\" id=\"p-4\">Autorii subliniaz\u0103 c\u0103 rezultatele indic\u0103 o asociere \u0219i nu demonstreaz\u0103 neap\u0103rat o rela\u021bie direct\u0103 de cauzalitate.<\/p>\n<h2 data-section-id=\"za7qt0\" data-start=\"1762\" data-end=\"1855\" id=\"chapter-1\"><span role=\"text\">Sute de cazuri raportate autorit\u0103\u021bilor<\/span><\/h2>\n<p data-start=\"1857\" data-end=\"2173\" id=\"p-5\">Potrivit cercet\u0103torilor, autorit\u0103\u021bile americane analizeaz\u0103 deja acest posibil semnal de siguran\u021b\u0103. Administra\u021bia pentru Alimente \u0219i Medicamente din SUA (FDA) a anun\u021bat c\u0103 evalueaz\u0103 raport\u0103rile privind apari\u021bia c\u0103derii p\u0103rului dup\u0103 ini\u021bierea tratamentului cu semaglutid\u0103 (Ozempic \u0219i Wegovy) \u0219i tirzepatid\u0103 (Mounjaro).<\/p>\n<p data-start=\"2175\" data-end=\"2421\" id=\"p-6\">\u00cen Marea Britanie, Agen\u021bia pentru Reglementarea Medicamentelor \u0219i a Produselor Medicale (MHRA) a primit, doar \u00een 2026, aproape 400 de raport\u0103ri privind c\u0103derea p\u0103rului asociat\u0103 cu tirzepatida, dup\u0103 alte 541 de cazuri \u00eenregistrate \u00een 2025.<\/p>\n<p data-start=\"2423\" data-end=\"2550\" id=\"p-7\">\u00cen ceea ce prive\u0219te semaglutida, autoritatea britanic\u0103 a primit 148 de raport\u0103ri \u00een 2026 \u0219i alte 164 \u00een anul precedent.<\/p>\n<h2 data-section-id=\"3f8b7v\" data-start=\"2552\" data-end=\"2634\" id=\"chapter-2\"><span role=\"text\">Care ar putea fi explica\u021bia<\/span><\/h2>\n<p data-start=\"2636\" data-end=\"2835\" id=\"p-8\">Cercet\u0103torii consider\u0103 c\u0103 cea mai probabil\u0103 explica\u021bie nu este efectul direct al medicamentelor asupra firului de p\u0103r, ci consecin\u021bele pierderii rapide \u00een greutate \u0219i ale reducerii aportului caloric.<\/p>\n<p data-start=\"2837\" data-end=\"3029\" id=\"p-9\">Restric\u021bia caloric\u0103 poate provoca stres fiziologic \u0219i deficien\u021be de micronutrien\u021bi esen\u021biali, precum fierul, zincul sau biotina, elemente importante pentru ciclul normal de cre\u0219tere a p\u0103rului.<\/p>\n<p data-start=\"3031\" data-end=\"3221\" id=\"p-10\">Totodat\u0103, speciali\u0219tii iau \u00een calcul \u0219i posibile efecte metabolice, hormonale sau imunologice ale medicamentelor GLP-1, care ar putea influen\u021ba dezvoltarea \u0219i regenerarea foliculilor de p\u0103r.<\/p>\n<p data-start=\"3223\" data-end=\"3636\" id=\"p-11\">Autorii studiului atrag aten\u021bia c\u0103, de\u0219i alopecia nu reprezint\u0103 \u00een general un risc major pentru s\u0103n\u0103tatea fizic\u0103, aceasta poate avea efecte importante asupra stimei de sine, calit\u0103\u021bii vie\u021bii \u0219i chiar asupra continuit\u0103\u021bii tratamentului. Ei subliniaz\u0103 c\u0103 sunt necesare cercet\u0103ri suplimentare pentru a stabili dac\u0103 exist\u0103 o rela\u021bie cauzal\u0103 direct\u0103 \u00eentre administrarea acestor medicamente \u0219i apari\u021bia c\u0103derii p\u0103rului.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cercetarea, realizat\u0103 de speciali\u0219ti de la Universitatea din Pennsylvania, sus\u021bine semnalele raportate anterior de autorit\u0103\u021bile de reglementare din Statele Unite \u0219i Marea Britanie. Oamenii de \u0219tiin\u021b\u0103 au analizat datele a &hellip; <a href=\"https:\/\/microscopemedia.com\/?p=704947\" class=\"more-link\">Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":704948,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts\/704947"}],"collection":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=704947"}],"version-history":[{"count":0,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts\/704947\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/media\/704948"}],"wp:attachment":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=704947"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=704947"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=704947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}